US EditionNew WHO Guidelines Recommend Injectable Lenacapavir for HIV Prevention
GLOBAL, JUL 14 – WHO urges rapid adoption of lenacapavir injection to address stagnant HIV prevention amid 1.3 million new infections and 40.8 million living with HIV globally in 2024.
- On July 14, 2025, during the IAS 2025 conference in Kigali, WHO announced new guidelines recommending injectable lenacapavir twice yearly for HIV prevention.
- This recommendation follows the recent FDA approval of LEN and emerges amid major funding cuts disrupting global HIV treatment and prevention programs.
- LEN offers a long-acting alternative to daily oral pills, shown in trials to prevent nearly all HIV infections, benefiting those with adherence or access challenges.
- WHO Director-General Tedros Ghebreyesus called LEN "the next best thing" in HIV prevention as 1.3 million new HIV infections occurred globally in 2024.
- WHO urged governments and partners to urgently roll out LEN within national programs, emphasizing bold, equitable implementation despite ongoing financial and social barriers.
31 Articles
31 Articles
WHO approves biannual HIV injection for global use
WHO emphasised the urgent need to make LEN widely accessible, through pharmacies, clinics, and online consultations, especially as global HIV prevention efforts are faltering The post WHO approves biannual HIV injection for global use appeared first on Premium Times Nigeria.
Africa: Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To Action
New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck's once-monthly oral pill MK-8527 advances to Phase 3 trials in Africa
WHO supports immediate rollout of new HIV jab
The World Health Organization (WHO) has officially recommended the global rollout of injectable lenacapavir (LEN), a long-acting HIV prevention jab that only needs to be taken twice a year. The announcement was made on Monday, July 14, 2025, during the 13th International AIDS Society Conference (IAS 2025) in Kigali, Rwanda. “While an HIV vaccine remains elusive, lenacapavir is the next best… Source
New WHO guidelines recommend injectable lenacapavir for HIV prevention
The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.
The World Health Organization (WHO) recommended that countries include lenacapavir for the prevention of human immunodeficiency virus (HIV). The drug was recently approved and is considered a tool to combat HIV infections, especially for groups at higher risk and in high-burden areas of the disease. The global recommendation, issued Monday at the International AIDS Conference in Kigali, Rwanda, comes about a month after the US Food and Drug Admi…
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
